These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 27798773)

  • 1. Chemosaturation Percutaneous Hepatic Perfusion: A Systematic Review.
    Vogel A; Gupta S; Zeile M; von Haken R; Brüning R; Lotz G; Vahrmeijer A; Vogl T; Wacker F
    Adv Ther; 2017 Jan; 33(12):2122-2138. PubMed ID: 27798773
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemosaturation with percutaneous hepatic perfusion is effective in patients with ocular melanoma and cholangiocarcinoma.
    Schönfeld L; Hinrichs JB; Marquardt S; Voigtländer T; Dewald C; Koppert W; Manns MP; Wacker F; Vogel A; Kirstein MM
    J Cancer Res Clin Oncol; 2020 Nov; 146(11):3003-3012. PubMed ID: 32564137
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemosaturation with percutaneous hepatic perfusions of melphalan for hepatic metastases: experience from two European centers.
    Vogl TJ; Zangos S; Scholtz JE; Schmitt F; Paetzold S; Trojan J; Orsi F; Lotz G; Ferrucci P
    Rofo; 2014 Oct; 186(10):937-44. PubMed ID: 24729409
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemosaturation with percutaneous hepatic perfusion of melphalan for liver-dominant metastatic uveal melanoma: a single center experience.
    Artzner C; Mossakowski O; Hefferman G; Grosse U; Hoffmann R; Forschner A; Eigentler T; Syha R; Grözinger G
    Cancer Imaging; 2019 May; 19(1):31. PubMed ID: 31146793
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of chemosaturation in patients with primary and secondary liver tumors.
    Kirstein MM; Marquardt S; Jedicke N; Marhenke S; Koppert W; Manns MP; Wacker F; Vogel A
    J Cancer Res Clin Oncol; 2017 Oct; 143(10):2113-2121. PubMed ID: 28634727
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety of Percutaneous Hepatic Perfusion with Melphalan in Patients with Unresectable Liver Metastases from Ocular Melanoma Using the Delcath Systems' Second-Generation Hemofiltration System: A Prospective Non-randomized Phase II Trial.
    Meijer TS; Burgmans MC; Fiocco M; de Geus-Oei LF; Kapiteijn E; de Leede EM; Martini CH; van der Meer RW; Tijl FGJ; Vahrmeijer AL
    Cardiovasc Intervent Radiol; 2019 Jun; 42(6):841-852. PubMed ID: 30767147
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Repeated percutaneous hepatic perfusion with melphalan can maintain long-term response in patients with liver cancers.
    Veelken R; Maiwald B; Strocka S; Petersen TO; Moche M; Ebel S; Denecke T; Rehak M; Struck MF; Forstmeyer D; Rademacher S; Seehofer D; Berg T; van Bömmel F
    Cardiovasc Intervent Radiol; 2022 Feb; 45(2):218-222. PubMed ID: 34716470
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Percutaneous isolated hepatic perfusion (chemosaturation) with melphalan following right hemihepatectomy in patients with cholangiocarcinoma and metastatic uveal melanoma: peri- and post-interventional adverse events and therapy response compared to a matched group without prior liver surgery.
    Dewald CLA; Becker LS; Maschke SK; Meine TC; Alten TA; Kirstein MM; Vogel A; Wacker FK; Meyer BC; Hinrichs JB
    Clin Exp Metastasis; 2020 Dec; 37(6):683-692. PubMed ID: 33034815
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemosaturation With Percutaneous Hepatic Perfusion in Unresectable Hepatic Metastases.
    Glazer ES; Zager JS
    Cancer Control; 2017 Jan; 24(1):96-101. PubMed ID: 28178721
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemosaturation with Percutaneous Hepatic Perfusion: Outcome and Safety in Patients with Metastasized Uveal Melanoma.
    Dewald CLA; Hinrichs JB; Becker LS; Maschke S; Meine TC; Saborowski A; Schönfeld LJ; Vogel A; Kirstein MM; Wacker FK
    Rofo; 2021 Aug; 193(8):928-936. PubMed ID: 33535258
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemosaturation with percutaneous hepatic perfusion for unresectable isolated hepatic metastases from sarcoma.
    Deneve JL; Choi J; Gonzalez RJ; Conley AP; Stewart S; Han D; Werner P; Chaudhry TA; Zager JS
    Cardiovasc Intervent Radiol; 2012 Dec; 35(6):1480-7. PubMed ID: 22699779
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Over 12 Years Single Institutional Experience Performing Percutaneous Hepatic Perfusion for Unresectable Liver Metastases.
    Carr MJ; Sun J; Cohen JB; Liu J; Serdiuk AA; Stewart SR; Doobay N; Duclos A; Seal DA; Choi J; Zager JS
    Cancer Control; 2020; 27(1):1073274820983019. PubMed ID: 33372814
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Results of a Randomized Controlled Multicenter Phase III Trial of Percutaneous Hepatic Perfusion Compared with Best Available Care for Patients with Melanoma Liver Metastases.
    Hughes MS; Zager J; Faries M; Alexander HR; Royal RE; Wood B; Choi J; McCluskey K; Whitman E; Agarwala S; Siskin G; Nutting C; Toomey MA; Webb C; Beresnev T; Pingpank JF
    Ann Surg Oncol; 2016 Apr; 23(4):1309-19. PubMed ID: 26597368
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospective Clinical and Pharmacological Evaluation of the Delcath System's Second-Generation (GEN2) Hemofiltration System in Patients Undergoing Percutaneous Hepatic Perfusion with Melphalan.
    de Leede EM; Burgmans MC; Meijer TS; Martini CH; Tijl FGJ; Vuyk J; van Erkel AR; van der Velde CJH; Kapiteijn E; Vahrmeijer AL
    Cardiovasc Intervent Radiol; 2017 Aug; 40(8):1196-1205. PubMed ID: 28451811
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Percutaneous hepatic perfusion (chemosaturation) with melphalan in patients with intrahepatic cholangiocarcinoma: European multicentre study on safety, short-term effects and survival.
    Marquardt S; Kirstein MM; Brüning R; Zeile M; Ferrucci PF; Prevoo W; Radeleff B; Trillaud H; Tselikas L; Vicente E; Wiggermann P; Manns MP; Vogel A; Wacker FK
    Eur Radiol; 2019 Apr; 29(4):1882-1892. PubMed ID: 30255257
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Percutaneous Hepatic Perfusion with Melphalan in Patients with Unresectable Ocular Melanoma Metastases Confined to the Liver: A Prospective Phase II Study.
    Meijer TS; Burgmans MC; de Leede EM; de Geus-Oei LF; Boekestijn B; Handgraaf HJM; Hilling DE; Lutjeboer J; Vuijk J; Martini CH; van Erkel AR; van der Meer RW; Tijl FGJ; Speetjens FM; Kapiteijn E; Vahrmeijer AL
    Ann Surg Oncol; 2021 Feb; 28(2):1130-1141. PubMed ID: 32761328
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and tolerability of chemosaturation in patients with hepatic metastases from uveal melanoma.
    Estler A; Artzner C; Bitzer M; Nikolaou K; Hoffmann R; Hepp T; Hagen F; Eigentler T; Forschner A; Grözinger G
    Acta Radiol; 2022 May; 63(5):577-585. PubMed ID: 34034537
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of melphalan, oxaliplatin, and paclitaxel in colon, liver, and gastric cancer cell lines in a short-term exposure model of chemosaturation therapy by percutaneous hepatic perfusion.
    Uzgare RP; Sheets TP; Johnston DS
    Anticancer Res; 2013 May; 33(5):1989-2000. PubMed ID: 23645748
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemosaturation of the Liver - an Update.
    Ebel S; Struck MF; van Boemmel F; Beeskow AB; Gößmann H; Denecke T
    Rofo; 2023 Jan; 195(1):30-37. PubMed ID: 35977553
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Percutaneous hepatic perfusion with melphalan in uveal melanoma: A safe and effective treatment modality in an orphan disease.
    Karydis I; Gangi A; Wheater MJ; Choi J; Wilson I; Thomas K; Pearce N; Takhar A; Gupta S; Hardman D; Sileno S; Stedman B; Zager JS; Ottensmeier C
    J Surg Oncol; 2018 May; 117(6):1170-1178. PubMed ID: 29284076
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.